95 related articles for article (PubMed ID: 9834062)
21. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
22. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
23. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
Gullo CA; Esser MT; Fuller CL; Lam Braciale V
J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
[TBL] [Abstract][Full Text] [Related]
24. H2-M3 presents a nonformylated viral epitope to CTLs generated in vitro.
Byers DE; Fischer Lindahl K
J Immunol; 1998 Jul; 161(1):90-6. PubMed ID: 9647211
[TBL] [Abstract][Full Text] [Related]
25. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
[TBL] [Abstract][Full Text] [Related]
26. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex.
Brooks JM; Colbert RA; Mear JP; Leese AM; Rickinson AB
J Immunol; 1998 Nov; 161(10):5252-9. PubMed ID: 9820497
[TBL] [Abstract][Full Text] [Related]
27. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
Wild J; Grusby MJ; Schirmbeck R; Reimann J
J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
[TBL] [Abstract][Full Text] [Related]
28. DNA immunization with 2C FMDV non-structural protein reveals the presence of an immunodominant CD8+, CTL epitope for Balb/c mice.
Barfoed AM; Rodriguez F; Therrien D; Borrego B; Sobrino F; Kamstrup S
Antiviral Res; 2006 Dec; 72(3):178-89. PubMed ID: 16890298
[TBL] [Abstract][Full Text] [Related]
29. Structural basis of Kbm8 alloreactivity. Amino acid substitutions on the beta-pleated floor of the antigen recognition site.
Hunt HD; Pullen JK; Dick RF; Bluestone JA; Pease LR
J Immunol; 1990 Sep; 145(5):1456-62. PubMed ID: 2384667
[TBL] [Abstract][Full Text] [Related]
30. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
31. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
Li X; Yang X; Jiang Y; Liu J
Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237
[TBL] [Abstract][Full Text] [Related]
32. Crystal structures of murine MHC Class I H-2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: implications for TCR repertoire selection and immunodominance.
Meijers R; Lai CC; Yang Y; Liu JH; Zhong W; Wang JH; Reinherz EL
J Mol Biol; 2005 Feb; 345(5):1099-110. PubMed ID: 15644207
[TBL] [Abstract][Full Text] [Related]
33. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
Toes RE; Offringa R; Blom RJ; Brandt RM; van der Eb AJ; Melief CJ; Kast WM
J Immunol; 1995 Apr; 154(7):3396-405. PubMed ID: 7534797
[TBL] [Abstract][Full Text] [Related]
34. Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL.
Gundlach BR; Wiesmüller KH; Junt T; Kienle S; Jung G; Walden P
J Immunol; 1996 May; 156(10):3645-51. PubMed ID: 8621898
[TBL] [Abstract][Full Text] [Related]
35. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice.
Sette AD; Oseroff C; Sidney J; Alexander J; Chesnut RW; Kakimi K; Guidotti LG; Chisari FV
J Immunol; 2001 Jan; 166(2):1389-97. PubMed ID: 11145724
[TBL] [Abstract][Full Text] [Related]
36. Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC monoclonal antibody.
Chung DH; Belyakov IM; Derby MA; Wang J; Boyd LF; Berzofsky JA; Margulies DH
J Immunol; 2001 Jul; 167(2):699-707. PubMed ID: 11441073
[TBL] [Abstract][Full Text] [Related]
37. Studies on the clonality of the response to an epitope of a protein antigen. Randomness of activation of epitope-recognizing clones and the development of clonal dominance.
Benjamini E; Andria ML; Estin CD; Norton FL; Leung CY
J Immunol; 1988 Jul; 141(1):55-63. PubMed ID: 2454264
[TBL] [Abstract][Full Text] [Related]
38. Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 beta of an MHC class I-restricted TCR.
Kalergis AM; Nathenson SG
J Immunol; 2000 Jul; 165(1):280-5. PubMed ID: 10861062
[TBL] [Abstract][Full Text] [Related]
39. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo.
Ando K; Guidotti LG; Wirth S; Ishikawa T; Missale G; Moriyama T; Schreiber RD; Schlicht HJ; Huang SN; Chisari FV
J Immunol; 1994 Apr; 152(7):3245-53. PubMed ID: 8144915
[TBL] [Abstract][Full Text] [Related]
40. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope.
Miles JJ; Borg NA; Brennan RM; Tynan FE; Kjer-Nielsen L; Silins SL; Bell MJ; Burrows JM; McCluskey J; Rossjohn J; Burrows SR
J Immunol; 2006 Nov; 177(10):6804-14. PubMed ID: 17082594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
